Matches in Wikidata for { <http://www.wikidata.org/entity/Q91302041> ?p ?o ?g. }
- Q91302041 description "2019 թվականի նոյեմբերի 12-ին հրատարակված գիտական հոդված" @default.
- Q91302041 description "article scientifique publié en 2019" @default.
- Q91302041 description "artículu científicu espublizáu en payares de 2019" @default.
- Q91302041 description "im November 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91302041 description "scientific article published on 12 November 2019" @default.
- Q91302041 description "wetenschappelijk artikel" @default.
- Q91302041 description "наукова стаття, опублікована 12 листопада 2019" @default.
- Q91302041 name "Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial" @default.
- Q91302041 name "Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial" @default.
- Q91302041 type Item @default.
- Q91302041 label "Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial" @default.
- Q91302041 label "Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial" @default.
- Q91302041 prefLabel "Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial" @default.
- Q91302041 prefLabel "Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial" @default.
- Q91302041 P1433 Q91302041-D5817097-971A-4780-80C8-8C9417F61A42 @default.
- Q91302041 P1476 Q91302041-6F5533C0-EFEE-4662-B159-1A8DB20B8846 @default.
- Q91302041 P2093 Q91302041-055B9ADB-36E3-4401-A6B6-F0B635ECC9FC @default.
- Q91302041 P2093 Q91302041-18D31C20-2663-4FE9-873E-C0FE2E592B66 @default.
- Q91302041 P2093 Q91302041-1C3B3CAA-CAF0-4DDE-9C40-025E6DA548BF @default.
- Q91302041 P2093 Q91302041-2E3E3680-2CBD-4B34-BB21-E3224B325BC4 @default.
- Q91302041 P2093 Q91302041-37C7A442-3293-4C86-A4B5-7A0FFA660BD0 @default.
- Q91302041 P2093 Q91302041-45F1E1AC-3FAF-4D05-99B3-8A8C1CAB60D0 @default.
- Q91302041 P2093 Q91302041-54A72DAE-2B17-4F7B-A93B-58F3E5DFAEFA @default.
- Q91302041 P2093 Q91302041-54B2C954-ED0C-46DA-A9B5-58DA482A53B5 @default.
- Q91302041 P2093 Q91302041-56743F11-F08F-4FF8-94D4-AF6A93B65AA7 @default.
- Q91302041 P2093 Q91302041-6451C5FC-669D-4827-A57D-0B472897C663 @default.
- Q91302041 P2093 Q91302041-6C0C6B92-76E8-47CB-AD54-409DCFD0F3E9 @default.
- Q91302041 P2093 Q91302041-712B65B1-919D-4075-BA8F-497F0BEC3DBD @default.
- Q91302041 P2093 Q91302041-857F9491-D59C-4BF6-AB11-EB08CA47A309 @default.
- Q91302041 P2093 Q91302041-AC2B949A-FB86-4056-A1D5-CAF07B787147 @default.
- Q91302041 P2093 Q91302041-B0B35CBF-D3E3-4037-A818-2B21D7F47AA2 @default.
- Q91302041 P2093 Q91302041-BDF0084D-5B7B-4E41-AA77-A84E560178EA @default.
- Q91302041 P2093 Q91302041-D737FB8E-4B23-438F-8522-2FE7C90F1751 @default.
- Q91302041 P2093 Q91302041-E45BD063-AF5F-4767-93FB-EEF8325621BE @default.
- Q91302041 P2093 Q91302041-F176BB38-AAD9-4509-B30A-AAD1E14A2E5E @default.
- Q91302041 P2860 Q91302041-0678495D-605A-4637-AF0B-B097E301964E @default.
- Q91302041 P2860 Q91302041-10356F9D-BFE5-4E8F-AF73-C856514EE509 @default.
- Q91302041 P2860 Q91302041-16AAEFEF-610A-4769-8F52-41759C69A5F6 @default.
- Q91302041 P2860 Q91302041-17D73651-7639-44E9-9427-60CE48D129D6 @default.
- Q91302041 P2860 Q91302041-2C55C473-9BAC-4112-AB0A-A9A06F07B553 @default.
- Q91302041 P2860 Q91302041-34562176-A1C6-490B-9221-C653E8339D59 @default.
- Q91302041 P2860 Q91302041-38EDAB01-CB83-4549-8D96-941141337D11 @default.
- Q91302041 P2860 Q91302041-475CB09E-F636-4B23-8682-A93B5D3E04A0 @default.
- Q91302041 P2860 Q91302041-4F5B16FE-929B-4F69-8DD2-5E0C40F08929 @default.
- Q91302041 P2860 Q91302041-670887B5-FABB-4E5E-9EB6-1B4BA71BDC2F @default.
- Q91302041 P2860 Q91302041-779FBFF9-768B-4D1C-A45B-7EAB6CB5E148 @default.
- Q91302041 P2860 Q91302041-7B20EB8F-48D8-445B-9D76-827B68FE799E @default.
- Q91302041 P2860 Q91302041-9244A352-FB20-49B0-B6A0-8F577204831B @default.
- Q91302041 P2860 Q91302041-B208522D-877B-4B01-B20B-84BCFDE66D22 @default.
- Q91302041 P2860 Q91302041-B754399D-66A8-4424-B28F-3745FFAC3EF9 @default.
- Q91302041 P2860 Q91302041-C985880C-921F-4EB5-AF29-52B9326939F8 @default.
- Q91302041 P2860 Q91302041-CA993C19-6405-480D-AED2-2A41F9174ABB @default.
- Q91302041 P2860 Q91302041-D3B5C7C2-48BE-47B0-9622-33952B7C8E6C @default.
- Q91302041 P2860 Q91302041-D77D5E28-D169-4454-9EDD-54354CE85F51 @default.
- Q91302041 P2860 Q91302041-F2FE9DC4-1166-4BB5-91FD-9211608F37C2 @default.
- Q91302041 P2860 Q91302041-F3313CDA-2070-44D8-9BE0-61B12B269A65 @default.
- Q91302041 P2860 Q91302041-FE3331C1-09C5-4E27-A326-8D29753B9263 @default.
- Q91302041 P304 Q91302041-40304AE3-85CA-4328-816C-B19E3ED53C95 @default.
- Q91302041 P31 Q91302041-1DD358FB-5DC3-499B-9C25-355BE7F4835D @default.
- Q91302041 P356 Q91302041-1CD066F7-341E-41CB-9EDA-FA378866F667 @default.
- Q91302041 P433 Q91302041-445540D1-9F05-4013-80D4-AF60CBEDFAAF @default.
- Q91302041 P478 Q91302041-DAD53695-9B9B-4DA0-ADAF-621AFE7ACC6F @default.
- Q91302041 P50 Q91302041-51A8C509-11E3-4100-BFA0-1BDCD6223516 @default.
- Q91302041 P577 Q91302041-1D50D5D5-34FD-4692-81D4-DB4E3C10373A @default.
- Q91302041 P698 Q91302041-B77FECB6-4F79-4C77-B0B4-D5D002401383 @default.
- Q91302041 P921 Q91302041-02313EB4-4EBB-46A0-97FA-758B3FF29328 @default.
- Q91302041 P921 Q91302041-0373A059-E99A-4000-A1AA-CF4D2FFFE893 @default.
- Q91302041 P921 Q91302041-1926E234-2587-4907-B5F9-92579F9DD195 @default.
- Q91302041 P921 Q91302041-68871770-0EEF-49BA-B65B-C0F1D9553B6E @default.
- Q91302041 P921 Q91302041-DE02B96B-3C6C-48F7-BD38-18F61D2D39F3 @default.
- Q91302041 P932 Q91302041-14173ABD-DEE4-4985-8774-5CC2C465D02A @default.
- Q91302041 P356 S2213-2600(19)30366-2 @default.
- Q91302041 P698 31732485 @default.
- Q91302041 P1433 Q27724908 @default.
- Q91302041 P1476 "Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial" @default.
- Q91302041 P2093 "Almari Conradie" @default.
- Q91302041 P2093 "Alphonse Okwera" @default.
- Q91302041 P2093 "Andreas H Diacon" @default.
- Q91302041 P2093 "Angela M Crook" @default.
- Q91302041 P2093 "Carl M Mendel" @default.
- Q91302041 P2093 "Christo H van Niekerk" @default.
- Q91302041 P2093 "Conor D Tweed" @default.
- Q91302041 P2093 "Daniel E Everitt" @default.
- Q91302041 P2093 "Ebrahim Variava" @default.
- Q91302041 P2093 "Francesca Conradie" @default.
- Q91302041 P2093 "Frederick Haraka" @default.
- Q91302041 P2093 "Klaus Reither" @default.
- Q91302041 P2093 "Melvin Spigelman" @default.
- Q91302041 P2093 "Mengchun Li" @default.
- Q91302041 P2093 "Modulakgotla A Sebe" @default.
- Q91302041 P2093 "Mohammed S Rassool" @default.
- Q91302041 P2093 "Nyanda E Ntinginya" @default.
- Q91302041 P2093 "Rodney Dawson" @default.
- Q91302041 P2093 "Suzanne Staples" @default.
- Q91302041 P2860 Q26749428 @default.
- Q91302041 P2860 Q27011264 @default.
- Q91302041 P2860 Q28207601 @default.
- Q91302041 P2860 Q30436145 @default.
- Q91302041 P2860 Q30840887 @default.
- Q91302041 P2860 Q33837706 @default.